作者
Marius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, Sung-A Chang, Paul A Corris, J Simon R Gibbs, Ekkehard Grünig, Pavel Jansa, James R Klinger, David Langleben, Vallerie V McLaughlin, Gisela MB Meyer, Jaquelina Ota-Arakaki, Andrew J Peacock, Tomás Pulido, Stephan Rosenkranz, Carmine Dario Vizza, Anton Vonk-Noordegraaf, R James White, Mikyung Chang, Frank Kleinjung, Christian Meier, Karen Paraschin, Hossein Ardeschir Ghofrani, Gérald Simonneau, H Olschewski, M Delcroix, M Andrade-Lima, R de Amorim Corrêac, F Figueiredo Campos, J Ota Arakaki, G Meyer, R De Souza, D Langleben, H Al-Hiti, P Jansa, S Mellemkjær, F Bauer, D Montani, G Simonneau, D Drömann, HA Ghofrani, E Grünig, M Halank, M Held, MM Hoeper, H Klose, N Kneidinger, H Leuchte, C Opitz, S Rosenkranz, H Wilkens, H Wirtz, H Karvounis, G Pitsiou, S Orfanos, M d'Alto, S Ghio, CD Vizza, P Vitulo, T Nakayama, H Maki, S Tatebe, M de Los Rios Ibarra, T Pulido, A Van Dijk, A Vonk-Noordegraaf, T Roleder, G Castro, MJ Loureiro, S Robalo-Martins, JA Barberá, M Lázaro, GM Perez-Penate, A Román, CC Cheng, CH Hsu, HH Hsu, E Atahan, N Mogulkoc Bishop, NG Okumus, Z Onen, HJ Chang, SA Chang, JS Lee, HK Kim, JG Coghlan, PA Corris, AC Church, R Condliffe, JSR Gibbs, AJ Peacock, S Wort, R Allen, S Allen, R Awdish, RL Benza, S DeSouza, J Feldman, S Johri, JR Klinger, D Layish, J McConnell, VV McLaughlin, C Migliore, F Rahaghi, F Rischard, I Robbins, L Satterwhite, T Shah, R Sulica, RJ White
发表日期
2021/6/1
期刊
The Lancet Respiratory Medicine
卷号
9
期号
6
页码范围
573-584
出版商
Elsevier
简介
Background
Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. The aim of this trial was to assess the effects of switching to riociguat from PDE5i therapy versus continued PDE5i therapy in patients with PAH at intermediate risk of 1-year mortality.
Methods
Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) was an open-label, randomised controlled trial in 81 hospital-based pulmonary hypertension centres in 22 countries. The study enrolled patients aged 18–75 years with symptomatic PAH at intermediate risk of 1-year mortality (based on …
学术搜索中的文章
MM Hoeper, H Al-Hiti, RL Benza, SA Chang, PA Corris… - The Lancet Respiratory Medicine, 2021